Drug Database
IN

influenza vaccine

✓ Approved

LG Chem Ltd. · · Vaccine

What is influenza vaccine?

influenza vaccine is a vaccine developed by LG Chem Ltd.. It is approved for therapeutic indications via inhaled or injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyLG Chem Ltd.
Drug ClassVaccine, Large Molecules
Molecular Target, ,
RouteInhaled, Injectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, LG Chem Ltd.

Mechanism of Action

Molecular Targets

influenza vaccine acts on 3 molecular targets:

(M1)
(HA)
(neuraminidase, influenza A virus)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Related Research Articles

PubMedBMC public health2026-10-16

Enhancing knowledge on influenza and other pandemic threats for healthcare personnel readiness in Thailand, 2007-2024.

Sawanpanyalert Narumol N, Praphasiri Prabda P, Ditsungnoen Darunee D, Tantilipikara Peangpim P et al.

Healthcare personnel are often the first line of defense against emerging diseases. Enhancing knowledge on influenza for healthcare personnel is part of Thailand's influenza pandemic preparedness plan. Beginning in 2007, the Thailand Department of Medical Services organized trainings for Thai healthcare personnel in Bangkok and all regions of Thailand on prevention, diagnosis, treatment, and control of human seasonal, avian, and pandemic influenza. The curriculum included overviews on the global situation, clinical features and treatment, influenza epidemiology and burden in Thailand, influenza as a cause of pneumonia, laboratory diagnostics, impact of influenza in high-risk populations and increased risk for complications; influenza economic evaluation of seasonal influenza vaccination in Thailand, and immunization and planning for human influenza outbreaks. Topics initially focused on seasonal and pandemic influenza and expanded in scope to incorporate other pandemic threats, such as MERS-CoV and COVID-19. From August 2007 through December 2024, 114 trainings were conducted. A total of 26,422 attendees (range 10-700 per training) were trained, including clinicians, nurses, pharmacists, laboratory technicians, and public health scientists (professionals trained in epidemiology, disease surveillance, and health data analysis) from public and private hospitals from national, regional, provincial, and district levels in Bangkok and 41 provinces nationwide. During training sessions, participants reported that the program increased their readiness and self-reported confidence to respond to potential respiratory outbreaks. These capacity-building efforts contributed to a health workforce that was better positioned to respond to emerging respiratory threats, including the first wave of COVID-19. Educating healthcare personnel about prevention, diagnosis, treatment, and control of influenza is an important component of pandemic preparedness. Refresher courses or online tutorials may be needed periodically to maintain current knowledge.

PMID 42881450
Read full article →
PubMedDiagnostics (Basel, Switzerland)2026-10-16

Influenza in Pregnancy: From the Maternal Lung to the Placenta and Fetus.

Vlădăreanu Radu R, Borislavschi Andreea A, Moisă Emanuel E, Boț Mihaela M

Influenza in pregnancy is associated with a higher risk of severe respiratory disease and adverse maternal and perinatal outcomes, particularly later in gestation. This narrative review synthesizes evidence on epidemiology, pathophysiology, placental and fetal consequences, clinical presentation, diagnosis, antiviral management, and vaccination. Pregnancy involves dynamic immune adaptation together with reduced respiratory reserve, increased oxygen consumption, and cardiovascular changes that may amplify the effects of influenza pneumonia. Placental and fetal consequences appear to be mediated predominantly by maternal hypoxemia, fever, systemic inflammation, and hemodynamic disturbance; transplacental viral transmission is rare. Therefore, adverse fetal and neonatal outcomes are more closely linked to the severity and timing of maternal illness, placental dysfunction, and prematurity than to direct fetal infection. Prompt recognition is essential, and antiviral treatment should not await laboratory confirmation when influenza is suspected. Oseltamivir remains the preferred antiviral therapy and should be initiated as early as possible, including in patients presenting after 48 h with progressive or severe disease. Seasonal inactivated or recombinant influenza vaccination is the cornerstone of prevention, protecting both the mother and the infant through transplacental transfer of influenza-specific IgG. This integrated perspective supports vaccination, early diagnosis, and timely treatment to reduce maternal and perinatal risk.

PMID 42882405
Read full article →
PubMedAmerican family physician2026-10-16

Influenza: Prevention, Diagnosis, and Treatment.

Sur Denise K C DKC, Khoo Catherine Peony CP

Influenza is typically a self-limiting viral infection that causes symptoms such as fever, chills, cough, rhinitis, headache, sweats, myalgias, and malaise. However, serious illness and complications (eg, pneumonia, death) can occur, particularly in individuals with risk factors. Annual influenza vaccination is recommended for people 6 months and older, including pregnant individuals, who do not have a contraindication to the vaccine. Rapid diagnosis of influenza using point-of-care testing in select patients increases antiviral prescribing and decreases antibiotic prescribing in those with a positive result. However, a negative rapid test result does not exclude influenza. Although most patients do not require treatment for influenza, antivirals should be initiated as soon as possible for patients who are hospitalized, have severe or progressive illness, or are at high risk of complications. Treatment can be considered in symptomatic patients who are household contacts of individuals at high risk of complications or in symptomatic health care professionals who care for patients at risk. Postexposure chemoprophylaxis with antiviral therapies can be considered in individuals who are at risk for influenza complications. Oseltamivir and baloxavir marboxil are commonly recommended antiviral treatment options for influenza. Antiviral treatment is most effective if taken within 24 to 36 hours of symptom onset and reduces symptoms by approximately 20 hours. However, there is little to no evidence that it reduces complications of influenza.

PMID 42886183
Read full article →
PubMedMilitary medicine2026-10-16

The Case for Dedicated Vaccine Communication Training: A Survey of Military Pediatricians.

Auvil Daley D, Jones Katherine K, Ratusnik Rebecca R, Adams Daniel J DJ

Vaccine uncertainty is rising among families in the United States, even among military families. The ACGME mandates that pediatric residents be trained in effective communication strategies for patients and families hesitant about recommended vaccinations, yet few validated curriculum tools exist. We aimed to understand the current landscape of vaccine uncertainty experienced by military general pediatricians and see what communication strategies were routinely being implemented in clinical practice. In March 2025, 45 graduates of a mid-sized military pediatrics residency program from the years 2016-2024 who were currently practicing general pediatricians were invited to participate in a survey on vaccine communication in clinical practice. The survey was a mix of quantitative questions asking for experienced trends in vaccine uncertainty as well as open-ended questions about communication strategies being implemented. Three clinical researchers performed a manual thematic analysis of free-text answers to understand and quantify common themes. Thirty-seven general pediatricians (82%) responded, and 95% of those surveyed rated a curriculum during medical training on vaccine communication as "very" or "extremely important." Only 19% of physicians were able to recall formal training in addressing vaccine hesitancy during medical school, and only 62% during residency. The 3 most commonly declined vaccines were COVID-19, influenza, and HPV. Pediatricians reported using communication strategies focused on knowledge-sharing (65%), partnership with families (62%), and normalizing vaccines (40%). Common barriers to vaccine acceptance were mistrust and disinterest, most commonly with unwillingness to engage in a conversation. Most practicing military pediatricians who graduated from our residency program report a rise in vaccine uncertainty in their practice and agree that a residency curriculum on vaccine communication is highly important. Such curricula should encourage evidence-based communication styles using vaccine normalization while de-emphasizing the urge to combat misinformation using knowledge-sharing and should specifically address the most commonly declined immunizations.

PMID 42885154
Read full article →
PubMedWorld journal of pediatrics : WJP2026-10-16

Associations between parental generative artificial intelligence health-advice use and child vaccination uptake in Japan: an exploratory cross-sectional study.

Imanishi Yousuke Y, Iorini Maria M, Jwa Sinchul S, Sakamoto Masahiko M et al.

Parents increasingly use generative artificial intelligence (AI) for health information, but evidence on parental AI use and childhood vaccination is limited. We examined exploratory associations between regular parental AI health-advice use and childhood vaccination in Japan. This cross-sectional study analyzed 2025 nationwide survey data from children aged 1 to 17 years and parents, with a linked 2023-2025 sub-analysis. The exposure was regular parental use of generative AI for health advice at least a few times per month. Outcomes were age-appropriate measles-rubella (MR) vaccination and any mumps, influenza, or coronavirus disease 2019 (COVID-19) vaccination. Modified Poisson regression estimated adjusted prevalence ratios (aPRs) and 95% confidence interval (95% CI) with parent-level clustering and covariates. Among 8282 children and 5170 parents, 1278 (15.4%) had regular AI health-advice users as parents. AI use was not associated with age-appropriate MR vaccination (aPR 1.02; 95% CI 0.97-1.09), but was associated with three vaccines. The adjusted rates were 76.6 versus 72.7% (aPR 1.05, 95% CI 1.01-1.10) for mumps, 56.7% versus 49.0% (aPR 1.16, 95% CI 1.08-1.24) for influenza, 40.6% versus 30.9% (aPR 1.31, 95% CI 1.19-1.45) for COVID-19. The COVID-19 association was strongest among parents younger than 30 years (aPR 2.58; 95% CI 1.90-3.50; P for interaction < 0.001). In the linked sub-analysis, these associations persisted after adjustment for an available 2023 household-level prior vaccination marker and attitudes. Regular parental use of generative AI for health advice was associated with mumps, influenza, and COVID-19 vaccination, but not with age-appropriate MR vaccination. These exploratory, cross-sectional findings are observational associations. They may reflect digital health engagement, health information seeking, socioeconomic differences, or favorable attitudes, rather than vaccine-specific AI advice.

PMID 42881346
Read full article →
PubMedScandinavian journal of clinical and laboratory investigation2026-10-16

Vancomycin therapeutic drug monitoring: trends and seasonal patterns.

Larsson Anders A, Hallberg Pär P, Cedernaes Jonathan J, Hamberg Anna-Karin AK

Vancomycin is widely used for serious Gram-positive infections, but its narrow therapeutic index necessitates therapeutic drug monitoring (TDM). Over recent decades, monitoring has shifted from trough-based to AUC-guided dosing. This study investigated long-term trends in vancomycin concentrations, seasonal variation and the utility of patient medians as a laboratory quality tool. Serum vancomycin results (n = 59,445) from routine TDM at Akademiska Hospital, Uppsala, Sweden (2006-2024) were analyzed. Data included sampling date, age, sex and concentration. Measurements were performed using validated immunoassays (Architect ci8200 and Cobas Pro c503) with standard quality control. Annual medians and percentiles were calculated, and seasonal variation was assessed. The number of analyses increased from 2,263 (2006) to 4,164 (2015), then declined to 2,414 (2024). Median concentrations and distribution percentiles rose steadily from 2006 to 2015 and remained stable thereafter. Seasonal variation showed a ∼15% decrease in testing volume during July-August, while concentration percentiles remained consistent throughout the year. Vancomycin concentrations in routine TDM increased until 2015 and have since stabilized, despite seasonal variation in test volume. Patient medians were stable over time and may serve as a useful complement to traditional quality control, particularly when standard materials do not fully represent patient samples.

PMID 42886031
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about influenza vaccine